A5049158191- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- CNS Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Retinoids in leukemia and cellular processes
- Lung Cancer Treatments and Mutations
- Acute Lymphoblastic Leukemia research
- Protein Degradation and Inhibitors
- Cutaneous lymphoproliferative disorders research
- Eosinophilic Disorders and Syndromes
- Histone Deacetylase Inhibitors Research
- Multiple and Secondary Primary Cancers
- Immunodeficiency and Autoimmune Disorders
- Platelet Disorders and Treatments
- Peptidase Inhibition and Analysis
- Hepatitis C virus research
- Hematological disorders and diagnostics
- Monoclonal and Polyclonal Antibodies Research
- T-cell and Retrovirus Studies
- Bone and Joint Diseases
- Ovarian cancer diagnosis and treatment
University of Modena and Reggio Emilia
2015-2024
Vita-Salute San Raffaele University
2024
Istituti di Ricovero e Cura a Carattere Scientifico
1986-2024
Regione Lombardia
2017-2024
Ente Regionale per i Servizi all'Agricoltura e alle Foreste
2024
Maasstad Ziekenhuis
2023
Erasmus MC
2023
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2023
University of Pavia
1973-2019
Fondazione Intergruppo Italiano Linfomi Onlus
2006-2015
Purpose Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL) requiring treatment, the optimal associated chemotherapy regimen has yet to be clarified. Patients and Methods We conducted an open-label, multicenter, randomized trial among adult previously untreated stages II IV FL compare efficacy of eight doses R cycles cyclophosphamide, vincristine, prednisone (CVP) or six doxorubicin, (CHOP) fludarabine mitoxantrone (FM). The principal end point study...
Hepatitis C virus (HCV) is endemic in some areas of Northwestern Europe and the United States. HCV has been shown to play a role development both hepatocellular carcinoma B-cell non-Hodgkin's lymphoma (B-NHL). The biologic mechanisms underlying lymphomagenic activity so far are under investigation. In this study, antiviral (anti-HCV) treatment B-NHL associated with infection evaluated.Thirteen patients histologically proven low-grade characterized by an indolent course (ie, doubling time no...
The prognoses of patients with chronic myelogenous leukemia in blastic phase (CML-BP) are extremely poor. Treatment nonlymphoid CML-BP is associated very low response rates, a median survival 2-3 months, and significant toxicities. aim this study was to evaluate the results therapy different treatments relation rate, survival, toxicity.A total 162 adults diagnosis referred from 1986 1997 were included analysis. Only first salvage considered for purpose CML defined by presence 30% or more...
PURPOSE Long-term treatment with interferon alfa (IFN alpha) can produce or exacerbate immune-mediated complications (IMC). The purpose of this study was to analyze the experience IMC and unusual in patients chronic myelogenous leukemia (CML) undergoing IFN alpha treatment. PATIENTS AND METHODS occurrence evaluated Philadelphia chromosome (Ph)-positive CML. RESULTS Well-documented clinically evident developed 35 after a median 14 months These included 28 (5%) 581 Ph-positive CML treated...
Abstract BACKGROUND: The combination of fludarabine, cyclophosphamide, and rituximab (FCR) has produced promising results in chronic lymphocytic leukemia other lymphoproliferative disorders. authors report the final from a multicenter, prospective study examining FCR Waldenstrom macroglobulinemia (WM). METHODS: Forty‐three patients with symptomatic WM that was untreated or pretreated 1 line chemotherapy received 375 mg/m 2 intravenously on day fludarabine 25 cyclophosphamide 250 days through...
Relatively little information is available on the incidence of secondary cancer in non-Hodgkin's lymphoma. The aim this long-term follow-up study was to determine incidence, time free second tumors, and risk factors for developing a homogeneous group patients with lymphoma.We evaluated total 563 indolent lymphoma enrolled Gruppo Italiano Studio Linfomi trials from 1988 2003.After median 62 months, 39 (6.9%) developed cancer: 12 myelodysplastic syndromes/acute myeloid leukemia, 27 solid...
A prospective, multicenter, randomized trial comparing pamidronate administration (60–90 mg once a month for 1 year) versus simple observation in 177 patients with asymptomatic myeloma was performed to explore whether the of this drug reduces rate and/or time progression overt, symptomatic disease. No relevant side effects were recorded pamidronate-treated patients. With minimum follow-up 5 years live patients, there 56/89 (62.9%) progressions group and 55/88 (62.5%) within controls (p =...
In this study we assessed the prognostic significance of absolute monocyte count and selected best cut-off value at diagnosis in a large cohort patients with diffuse B-cell lymphoma. Data were retrieved for therapy-naïve lymphoma followed Israel Italy during 1993–2010. A final 1017 was analyzed median follow up 48 months 5-year overall survival rate 68%. The level 630/mm3 counts below 71%, whereas it 59% those >630 mm3 (P=0.0002). Of patients, 521 (51%) treated chemo-immunotherapy, cohort,...
Summary Novel treatments for multiple myeloma ( MM ) have shown promising results in clinical trials, but the advantage unselected patients is still unclear. In order to evaluate whether novel therapies impact survival of patients, we performed a population‐based analysis on data collected by M odena C ancer R egistry from 1989 2009. The evaluated 1206 newly diagnosed years 1988–96 (conventional therapy), 1997–05 (high dose melphalan and autologous transplant), 2006–09 (novel agents era)....
Abstract Several studies have demonstrated the prognostic value of neutrophil‐lymphocyte ratio (NLR) in patients with solid tumors and non–Hodgkin lymphoma. In contrast, there is only sparse data on its role classical Hodgkin lymphoma (cHL). The aim our study was to establish whether NLR could serve as an independent factor a cohort 990 nodular sclerosis (NS)‐cHL. After analysis log hazard (HR) function NLR, we chose 6 cutoff. Patients >6 had worse progression‐free survival overall...
Abstract BACKGROUND. It is unclear whether new treatment modalities have improved the survival of follicular lymphoma patients. Some data show that there has been no improvement in last 3 decades 20th century, whereas results recent retrospective studies suggest evolving therapy outcome for METHODS. To evaluate impact therapies lymphoma, particularly introduction rituximab, overall (OS), failure‐free (FFS), and after recurrence (SAR) was analyzed 438 advanced‐stage patients enrolled...
The effects of radiotherapy (RT) after chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL) remain unclear; several trials have yielded conflicting results. This study examined the effect RT cyclophosphamide, doxorubicin, vincristine, and prednisone + rituximab (R-CHOP) treatment on event-free (EFS) overall (OS) survival. Data from 216 DLBCL who were enrolled two clinical at Italian Lymphoma Study Group sites subjected to six R-CHOP cycles involved-field (IFRT) retrospectively...
To verify whether absolute monocyte count (AMC) and lymphocyte- ratio (LMR) at diagnosis are valid prognostic parameters in classical Hodgkin lymphoma (cHL).Data were collected from 1450 patients with cHL treated Israel Italy January 1, 1988, through December 31, 2007.The median age of the was 33 years (range, 17-72 years), 70% (1017) had nodular sclerosis (NS); follow-up duration 87 months. The best cutoff value for AMC 750 cells/mm(3), LMR 2.1. adverse impact an more than cells/mm(3)...
We investigated the cytotoxic interactions of romidepsin, a histone deacetylase inhibitor, and lenalidomide, an immunomodulatory agent, in T-cell lymphoma preclinical model. Hut-78 Karpas-299 cells were treated with romidepsin lenalidomide alone combination. The interaction between was evaluated by Chou–Talalay method, cell viability clonogenicity also evaluated. Apoptosis, reactive oxygen species (ROS) levels, cycle distribution determined flow cytometry. ER stress, caspase activation, AKT,...
The monoclonal antibody Ki‐67, directed against a nuclear antigen expressed by dividing cells in all the phases of cell cycle except G0 and early G1, was used combination with an anti‐BrdU antibody, reacting selectively S‐phase, for assessing percentage proliferating bone marrow peripheral blood samples from patients lymphoma, leukaemia multiple myeloma. Immunocytochemical labelling performed on frozen sections and/or cytospins using immunoalkaline phosphatase (APAAP) technique that made it...
Evolving therapies have improved the prognoses of patients with breast cancer; and currently, number long-term survivors is continuously increasing. However, these are at increased risk developing a second cancer. Thus, late side effects becoming an important issue. In this study, we aimed to investigate whether patient tumor characteristics, treatment type correlate secondary risk.